CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Acute Myeloid Leukemia With Myelodysplasia-Related Changes Clinical Trial

Official title:
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Status Recruiting

Clinical Trial Summary

This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acute Myelogenous Leukemia (AML) Due to Therapy
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute

Clinical Trial Details

NCT number	NCT04231851
Study type	Interventional
Source	University of California, Irvine
Contact	Chao Family Comprehensive Cancer Center University of California
Phone	1-877-827-7883
Email	ucstudy@uci.edu
Status	Recruiting
Phase	Phase 2
Start date	February 19, 2020
Completion date	September 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03526926` - A Post-Marketing Observational Study of VYXEOS™
Completed	`NCT00416598` - Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT02727803` - Personalized NK Cell Therapy in CBT	Phase 2
Recruiting	`NCT04269213` - CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	Phase 2
Recruiting	`NCT06143839` - VYxeoS Liposomal Italian Observational Study iN the Real Practice
Active, not recruiting	`NCT03330821` - Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Phase 1/Phase 2